Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DTwP-HepB-Hib Vaccine · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| DTwP-HepB-Hib Vaccine | BIOLOGICAL | Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age. |
Inclusion Criteria: 1. Male and female subjects ≥ 42 days to ≤ 64 days of age. 2. Written informed consent obtained from either parents/ legal guardian after the nature of the study has been explained according to local regulatory requirements Exclusion Criteria: 1. Subjects whose parents or lega...
DTwP-HepB-Hib Vaccine is a fully liquid pentavalent vaccine used for immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type B. It is being developed for use in infants as young as 6 to 8 weeks of age.
DTwP-HepB-Hib Vaccine is being developed by Novartis AG, which trades under the ticker NVS. The vaccine is currently in Phase 3 clinical development for the prevention of diphtheria and other infectious diseases.
DTwP-HepB-Hib Vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed, and the vaccine remains under clinical investigation.
DTwP-HepB-Hib Vaccine has one completed Phase 3 trial, NCT01470287, which evaluated its immunogenicity, safety, and tolerability in infants 6 to 8 weeks of age. The trial enrolled 175 participants in India and was an uncontrolled, non-randomized study.
Yes, DTwP-HepB-Hib Vaccine is a fully liquid pentavalent vaccine, meaning it combines five antigens in one formulation. It protects against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type B, offering broad coverage in a single injection.